Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-880-8 | CAS number: 176972-62-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Study period:
- November 10, 1997 to August 13, 1998
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was conducted according to GLP and per OECD Guideline 407.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Chlorohydrine Intermediate
- IUPAC Name:
- Chlorohydrine Intermediate
- Details on test material:
- The test material Chlorohydrine Intermediate was received from the Sponsor on October 2 1, 1997, and stored at room temperature. It was described as a white powder.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD (SD)BR
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: methylcellulose
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
Results and discussion
Effect levels
- Dose descriptor:
- other: A no-observable-effect level (NOEL) was not observed.
- Remarks on result:
- not measured/tested
- Remarks:
- Effect level not specified (migrated information)
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Eight 1000 mg/kg/day (five males; three females) rats died between study Days 3 and 5. Among the signs preceeding death were ataxia, hypoactivity, and convulsion (females only). Histologically, centrolobular coagulative necrosis and congestion were observed in the livers of almost all of these animals and were likely related to the cause of death.
Biologically important clinical signs in animals that survived until the scheduled sacrifice were restricted to the 1000 mg/kg/day group. These consisted of ataxia (not observed after Day 13), hypoactivity (not observed after Day 1 l), convulsions (females only; not observed after Day 4), and rough haircoat. No clinically significant ophthalmic changes were found.
The mean body weight of 1000 mg/kg/day males was significantly lower than that of control males from the beginning of Week 2 onward. This difference reflected an extremely low mean food consumption for this group during Week 1 that was accompanied by an actual loss in the group mean body weight. During Week 2. This group’s mean food consumption, as a percentage of the mean body weight at the beginning of the week, was markedly higher than that of the control group and the mean body weight change was significantly higher than the control value. In subsequent weeks, the mean food consumption and body weight, as a percentage of the mean body weight at the beginning of the week, of 1000 mg/kg/day males were similar to that of the control group. Significantly lower mean food consumption values were also observed in 200 and 500 mg/kg/day males during Week 1) with a significantly lower mean body weight change occurring for 500 mg/kg/day males. No corresponding clinical signs were observed in these groups. The absence of these clinical signs or meaningful mean body weight and food consumption differences during Weeks 3 and 4 in the 1000 mg/kg/day group and the less severe pattern in the 200 and 500 mg/kg/day groups suggest a transient dose-related toxic or pharmacological effect followed by adaption.
In females, a similar, but less severe, pattern was observed. Mean food consumption values for the 500 and 1000 mg/kg/day groups were significantly lower than that of the control group during Week 1. The mean food consumption value of the 200 mg/kg/day group was also low during Week 1. The mean body weight change of the 1000 mg/kg/day group was significantly lower than that of the control group during Week 1. During Week 2, the mean body weight change for the 500 and 1000 mg/kg/day groups, as a percentage of the mean body weight at the beginning of the week, was higher than that of the control group. Clinical signs observed in 1000 mg/kg/day females during this period included convulsions, hypoactivity, and ataxia. As with the males, this pattern suggests a transient dose-related toxic or pharmacological effect followed by adaption.
Treatment-related, often significant, alterations in the mean clinical pathology data included increases in segmented neutrophil counts in 1000 mg/kg/day animals and monocytes in 1000 mg/kg/day males, alanine aminotransferase: aspartate aminotransferase, gamma glutamyltransferase, and triglycerides in 1000 mg/kg/day animals, and total cholesterol in 200, 500, and 1000 mg/kg/day animals. Possible treatment-related lower mean platelet counts were observed in 500 mg/kg/day males and 1000 mg/kg/day animals. Possibly indirectly related to the test material were significantly higher mean values for total protein and albumin in 500 and 1000 mg/kg/day females and globulin in 1000 mg/kg/day females. These changes suggest
hemoconcentration due to dehydration.
Generally, liver weights in all groups that received the test material were higher than the sex-matched control value. This elevation was dose related, biologically significant, and clearly related to the histomorphological changes observed. Adrenal weights in 500 and 1000 mg/kg/day females were elevated in a stepwise fashion. No histomorphological correlate was observed in 1000 mg/kg/day female adrenals.
Biologically significant macroscopic organ changes were restricted to the liver and consisted of enlargement, particularly in 1000 mg/kg/day animals, and dark appearance. Histomorphologically, a dose-related centrolobular hepatocellular hypertrophy was present in all groups that received the chlorohydrine intermediate. In addition, in the 1000 mg/kg/day group, a centrolobular coagulative necrosis with an accompanying chronic active inflammation was observed.
Applicant's summary and conclusion
- Conclusions:
- In summary, oral gavage with the chlorohydrine intermediate for at least 28 days in rats resulted in mortality (1000 mg/kg/day); differences in clinical signs (1000 mg/kg/day), body weight (1000 mg/kg/day), body weight change (500 mg/kg/day males; 1000 mg/kg/day animals), and food consumption (200, 500, 1000 mg/kg/day); hematology (1000 mg/kg/day); hepatocellular and hepatocellular-related serum chemistries (200,500, 1000 mg/kg/day); liver weights (200, 500, 1000 mg/kg/day); female adrenal weights (500, 1000 mg/kg/day); hepatocellular size (200, 500. and 1000 mg/kg/day); and hepatocellular integrity (1000 mg/kg/day). Taken together, these changes are consistent with an acute hepatocellular toxicity and, at 1000 mg/kg/day, a possible secondary hepatic encephalopathy, which can lead to either death or adaptation.
A no-observable-effect level (NOEL) was not observed. - Executive summary:
This study was designed to evaluate the toxicity of a chlorohydrine intermediate, when administered daily by oral gavage to rats for at least 28 days.
Male and female Crl:CD (SD)BR rats were assigned to 4 groups (1 O/sex in Groups 1 and 4; S/sex in Groups 2 and 3). Groups 2, 3, and 4 received, respectively, 200, 500, or 1000 mg/kg/day of the test material in a methylcellulose-water vehicle. Group 1 served as a concurrent control and received the vehicle alone.
Diet and water were provided ad libitum. The animals were observed twice daily (a.m. and p.m.) for mortality and moribundity. During Days 1-14, each animal was observed for signs of toxicity at approximately 1 hour postdose. In addition, at least once each week, each animal was removed from its cage and examined for abnormalities and signs of toxicity. Body weights and food consumption data were collected weekly. Ophthalmic examinations were done before initiation of treatment and at termination. Blood samples were collected for hematology and clinical chemistry tests at the termination of treatment. After at least 28 days of treatment, the animals were anesthetized, weighed, exsanguinated, and necropsied. At necropsy, macroscopic observations were recorded, selected organs were weighed, and selected tissues were collected and preserved. Animals that died on test or were sacrificed at an unscheduled interval were also necropsied. Tissues from each animal in Groups 1 and 4 and from each animal that died or was sacrificed at an unscheduled interval were examined histologically. Macroscopic lesions, liver, and kidneys were also examined microscopically from each animal in Groups 2 and 3.
Eight 1000 mg/kg/day (five males; three females) rats died between study Days 3 and 5. Among the signs preceeding death were ataxia, hypoactivity, and convulsion (females only). Histologically, centrolobular coagulative necrosis and congestion were observed in the livers of almost all of these animals and were likely related to the cause of death.
Biologically important clinical signs in animals that survived until the scheduled sacrifice were restricted to the 1000 mg/kg/day group. These consisted of ataxia (not observed after Day 13), hypoactivity (not observed after Day 1 l), convulsions (females only; not observed after Day 4), and rough haircoat. No clinically significant ophthalmic changes were found.
The mean body weight of 1000 mg/kg/day males was significantly lower than that of control males from the beginning of Week 2 onward. This difference reflected an extremely low mean food consumption for this group during Week 1 that was accompanied by an actual loss in the group mean body weight. During Week 2. This group’s mean food consumption, as a percentage of the mean body weight at the beginning of the week, was markedly higher than that of the control group and the mean body weight change was significantly higher than the control value. In subsequent weeks, the mean food consumption and body weight, as a percentage of the mean body weight at the beginning of the week, of 1000 mg/kg/day males were similar to that of the control group. Significantly lower mean food consumption values were also observed in 200 and 500 mg/kg/day males during Week 1) with a significantly lower mean body weight change occurring for 500 mg/kg/day males. No corresponding clinical signs were observed in these groups. The absence of these clinical signs or meaningful mean body weight and food consumption differences during Weeks 3 and 4 in the 1000 mg/kg/day group and the less severe pattern in the 200 and 500 mg/kg/day groups suggest a transient dose-related toxic or pharmacological effect followed by adaption.
In females, a similar, but less severe, pattern was observed. Mean food consumption values for the 500 and 1000 mg/kg/day groups were significantly lower than that of the control group during Week 1. The mean food consumption value of the 200 mg/kg/day group was also low during Week 1. The mean body weight change of the 1000 mg/kg/day group was significantly lower than that of the control group during Week 1. During Week 2, the mean body weight change for the 500 and 1000 mg/kg/day groups, as a percentage of the mean body weight at the beginning of the week, was higher than that of the control group. Clinical signs observed in 1000 mg/kg/day females during this period included convulsions, hypoactivity, and ataxia. As with the males, this pattern suggests a transient dose-related toxic or pharmacological effect followed by adaption.
Treatment-related, often significant, alterations in the mean clinical pathology data included increases in segmented neutrophil counts in 1000 mg/kg/day animals and monocytes in 1000 mg/kg/day males, alanine aminotransferase: aspartate aminotransferase, gamma glutamyltransferase, and triglycerides in 1000 mg/kg/day animals, and total cholesterol in 200, 500, and 1000 mg/kg/day animals. Possible treatment-related lower mean platelet counts were observed in 500 mg/kg/day males and 1000 mg/kg/day animals. Possibly indirectly related to the test material were significantly higher mean values for total protein and albumin in 500 and 1000 mg/kg/day females and globulin in 1000 mg/kg/day females. These changes suggest
hemoconcentration due to dehydration.
Generally, liver weights in all groups that received the test material were higher than the sex-matched control value. This elevation was dose related, biologically significant, and clearly related to the histomorphological changes observed. Adrenal weights in 500 and 1000 mg/kg/day females were elevated in a stepwise fashion. No histomorphological correlate was observed in 1000 mg/kg/day female adrenals.
Biologically significant macroscopic organ changes were restricted to the liver and consisted of enlargement, particularly in 1000 mg/kg/day animals, and dark appearance. Histomorphologically, a dose-related centrolobular hepatocellular hypertrophy was present in all groups that received the chlorohydrine intermediate. In addition, in the 1000 mg/kg/day group, a centrolobular coagulative necrosis with an accompanying chronic active inflammation was observed.
In summary, oral gavage with the chlorohydrine intermediate for at least 28 days in rats resulted in mortality (1000 mg/kg/day); differences in clinical signs (1000 mg/kg/day), body weight (1000 mg/kg/day), body weight change (500 mg/kg/day males; 1000 mg/kg/day animals), and food consumption (200, 500, 1000 mg/kg/day); hematology (1000 mg/kg/day); hepatocellular and hepatocellular-related serum chemistries (200,500, 1000 mg/kg/day); liver weights (200, 500, 1000 mg/kg/day); female adrenal weights (500, 1000 mg/kg/day); hepatocellular size (200, 500. and 1000 mg/kg/day); and hepatocellular integrity (1000 mg/kg/day). Taken together, these changes are consistent with an acute hepatocellular toxicity and, at 1000 mg/kg/day, a possible secondary hepatic encephalopathy, which can lead to either death or adaptation.
A no-observable-effect level (NOEL) was not observed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.